A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation

Acta Psychiatrica Scandinavica

Volumn 130, Issue 1, 2014, Pages 61-68

  Pratts, M ^a   Citrome, L ^b   Grant, W ^c   Leso, L ^a   Opler, L A ^d  

^a ST JOSEPH S HOSPITAL HEALTH CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

Aggression; Agitation; Asenapine; Psychopharmacology; Psychoses

Indexed keywords

ASENAPINE; PLACEBO; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EMERGENCY WARD; FEMALE; HUMAN; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; ADOLESCENT; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR AGITATION; SUBLINGUAL DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902081175     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12262     Document Type: Article

References (13)

1. Citrome L, Volavka J. Clinical management of persistent aggressive behavior in Schizophrenia. Part I: Definitions, epidemiology, assessment, and acute treatment. Essential Psychopharmacol 2002;5:1-16.
2. Wilson MP, Pepper D, Currier GW, Holloman GHJR, Feifel D. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med 2012;13:26-34.
3. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68:1876-1885.
4. Citrome L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther Clin Risk Manag 2013;9:235-245.
5. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63:1762-1784.
6. Citrome L. Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatr Dis Treat 2011;7:325-339.
7. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
8. Lindenmayer JP, Brown E, Baker RW et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res 2004;68:331-337.
9. Montoya A, Valladares A, Lizán L, San L, Escobar R, Paz S. Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room. Health Qual Life Outcomes 2011;9:18.
10. Guy W. ECDEU assessment manual for psychopharmacology, revised. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:534-537.
11. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
12. El-Mallakh RS, McKenzie C. The dopamine D4/D2 receptor antagonist affinity ratio as a predictor of anti-aggression medication efficacy. Med Hypotheses 2013;80:530-533.
13. del Parigi A. Industry funded clinical trials: bias and quality. Curr Med Res Opin 2012;28:23-25.